Halozyme Therapeutics stock has delivered a 106.2% return over the past five years, yet the current valuation checks lean toward the shares looking rich on market multiples rather than clearly cheap.

• Over the last 5 years, Halozyme Therapeutics has returned 106.2%, which puts extra focus on whether recent gains already reflect much of the good news in the price.
• Recent record financial results and new collaboration agreements can support expectations for future revenue, while heavy share repurchases highlight capital returns but may also raise questions about how much flexibility the company has for other uses of cash.
• The stock earns a mixed verdict on valuation, with a score of 3 out of 6, which suggests neither a clear bargain nor clear overvaluation across the broader checks.

The issue now is whether Halozyme Therapeutics' strong share price run and recent news already leave limited room for further upside based on current fundamentals.

Is Halozyme Therapeutics Getting Expensive on Earnings?

The P/E ratio suits Halozyme Therapeutics because the company reports positive earnings and trades actively on profit-based metrics. Right now, Halozyme Therapeutics changes hands at about 29.2x earnings. That is above the biotech industry average of roughly 17.6x and below the broader peer group around 51.3x.

A fair P/E based on Halozyme Therapeutics' profile is estimated at about 20.1x, which is well under the current 29.2x. This suggests the shares screen as overvalued on earnings compared with what the model indicates for the company's growth, margins, size and risk. Despite record second quarter 2026 results and raised guidance this year, the market is already assigning a premium multiple to those earnings.

On the P/E yardstick, Halozyme Therapeutics stock currently screens as overvalued relative to its model-based fair level.

The Halozyme Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for Halozyme Therapeutics leaves off and explain what kind of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than today’s price. Rather than rely on a single multiple or model line, each narrative sets out its own assumptions for Halozyme Therapeutics' fair value so you can compare them with actual results as new numbers arrive.

One of the top community narratives on Halozyme Therapeutics: roughly fairly valued

"The company's expanding network of global partnerships and the ramp-up of recently launched subcutaneous biologics provide a robust set of new and diversified royalty streams..."

Do you think there's more to the story for Halozyme Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

Halozyme Therapeutics now trades on an earnings multiple that looks rich compared with its biotech peers and with what the fair P/E model implies. The broader checks lean toward the stock looking overvalued on current fundamentals rather than obviously mispriced. For you, the key question is whether Halozyme Therapeutics can deliver margins and earnings strong enough to keep justifying this premium, or whether the P/E eventually settles closer to the industry and reduces the potential for future returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.